Subacute combined degeneration
Conditions
Interventions
Gold Standard:Diagnosis of subacute combined degeneration was made in accordance with: (1) Subacute or chronic course, clinical symptoms suggesting lesions of and posterior columns of spinal cord and
(2) Serum vitamin B12 concentration determination below normal, or effective vitamin B12 trial treatment.clusion criteria: Other spinal cord diseases and peripheral neuropathies, severe abnormalities
Index test:Serum Hcy MCV MCH triple test
Sponsors
Beijing Yanhua Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Case group: Based on the 2020 "Consensus on the Diagnosis and Treatment of Subacute Combined Degeneration in China," the inclusion and exclusion criteria for this study are as follows: 1. Subacute or chronic onset, presenting with signs of damage to the posterior columns, lateral columns, and peripheral nerves; 2. Low serum vitamin B12 levels; for cases where serum vitamin B12 levels are not low but clinical manifestations are consistent with SCD, as long as there is a positive response to vitamin B12 treatment, they are still considered vitamin B12 deficient for inclusion. 3. Auxiliary examinations can exclude other similar myelopathies or peripheral neuropathies. Control group: Non-SCD myelopathy and peripheral neuropathy patients (including acute myelitis, optic neuritis, cervical spondylosis, spinal masses, syringomyelia, spinal tuberculosis, lumbar disease, diabetic peripheral neuropathy, etc.) and mildly affected patients from the neurology department (including primary headache, peripheral vertigo, essential tremor, trigeminal neuralgia, etc.) who were admitted to our hospital at the same time were selected as the control group. After matching the control group for age, gender, and other factors, the number of cases collected was comparable to that of the case group.
Exclusion criteria
Exclusion criteria: 1.Poor compliance; 2.Severe abnormalities of hepatic and renal functions; 3.Severe sequelae of nervous system diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total homocysteine;Sensitivity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete blood count; | — |
Countries
China
Contacts
Public ContactZhang Xiaofang
Beijing Yanhua Hospital
Outcome results
None listed